Advertisement

Topics

Search Results for "CT P6 Celltrion"

10:01 EDT 29th July 2016 | BioPortfolio

Matching Channels

None

Matching News

Celltrion Expects Korea Rituximab Approval Despite Biogen Action

Biogen moves to halt Celltrion from selling a rituximab biosimilar in South Korea by seeking a patent scope confirmation trial as the South Korean firm gears up to launch its second biosimilar. But Ce...

Korea stock? Celltrion stores Remicade biosimilar but minimises risks

Celltrion’s supply chain and warehousing procedures ensure the safe storage of Remicade biosimilars as demand fluctuates across markets, the drugmaker says.

US Panel Favors Celltrion’s Infliximab But Skeptical On Cost Savings

With the favorable backing of a US FDA advisory panel on Feb. 9, which followed a positive review by regulators, Celltrion and its partner, Pfizer unit Hospira, are well on their way to putting the fi...

Real-world biosimilar data driving physician acceptance, says Celltrion

Biosimilar acceptance among physicians has doubled to 80% since 2013, according to a survey presented at by copycat biologic distributor Celltrion Healthcare.

Celltrion: Data support switching to Remicade biosimilar

Celltrion Inc. (KOSDAQ:068270) presented data from 10 real-world switching studies showing that biosimilar infliximab (CT-P13) had "comparable efficacy and safety" to reference product Remicade inflix...

Celltrion Biosimilar Package Strong, But How Many Indications Will It Get?

Like Zarxio before it, Celltrion’s biosimilar infliximab product Inflectra is coming before a US advisory committee having received a glowing review from FDA staff; but the key question seems to be ...

Pfizer introduces first and only biosimilar monoclonal antibody therapy

Michael JohnsenHospira, now a Pfizer company, entered into an agreement with Celltrion and Celltrion Healthcare in 2009 for several potential biosimilar products, including the recently-approved Infle...

Celltrion’s Biosimilar to Remicade Likely to be Approved for All Indications

There are no clinically meaningful differences between Celltrion’s CT-P13 and Remicade, according to an FDA briefing released ahead of the formal panel meeting. Date:  Tue, 2016-02-09 (All d...

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement